2269N Stock Chart & Stats
$66.00
$0.00(0.00%)
At close: 4:00 PM EDT
$66.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$66.00 - $66.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$442.25B
Enterprise Value$140.19K
Total Cash (Recent Filing)$13.04B
Total Debt (Recent Filing)$2.73B
Price to Earnings (P/E)34.8
Beta0.00
Next Earnings
Mar 23, 2027EPS Estimate
1.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.21
Shares Outstanding4,152,929,700
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)2.49
Price to Sales (P/S)5.41
P/FCF Ratio42.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$124.56Price Target Upside88.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)3.04
Revenue Forecast (FY)$55.55B
Bulls Say, Bears Say
Bulls Say
Healthy ProfitabilityStrong 2025 gross, EBIT, and net margins show that the CDMO model is currently generating meaningful profit from its service platform. This profitability provides internal resources for research, capacity, and operational investment while supporting resilience across development and manufacturing activities.
Conservative Balance SheetVery low and improving leverage reduces the company’s dependence on borrowing and preserves financial flexibility. A sizeable equity base and growing assets provide support for continued investment in biologics capabilities, while limited debt reduces pressure from financing costs during periods of uneven demand.
Integrated Biologics PlatformThe broad service offering lets customers access multiple stages of the biologics lifecycle through one provider, from preclinical work to commercial supply. That integrated position can deepen customer relationships, increase opportunities for follow-on work, and support participation as successful molecules advance.
Bears Say
Recent Growth DecelerationThe sharp slowdown in annual revenue growth indicates that prior expansion has not recently translated into the same pace of top-line progress. If sustained, slower project or customer growth could reduce operating leverage and limit the rate at which the company expands its biologics platform.
Weak And Volatile Cash ConversionAlthough cash generation improved in 2025, free cash flow remains materially below reported earnings and operating cash flow also trails net income. Earlier periods of negative free cash flow show that investment and working-capital demands can make cash realization uneven, limiting financial predictability.
Margins Below Historical PeaksCurrent margins remain healthy, but the gap from 2021–2022 peak levels suggests that profitability has normalized or faced mix and cost pressure. Sustained margin recovery may therefore require stronger utilization, pricing, or project mix rather than relying only on revenue growth.
Wuxi Biologics (Cayman) News
2269N FAQ
What was Wuxi Biologics (Cayman) Inc.’s price range in the past 12 months?
Wuxi Biologics (Cayman) Inc. lowest stock price was $66.00 and its highest was $66.00 in the past 12 months.
What is Wuxi Biologics (Cayman) Inc.’s market cap?
Wuxi Biologics (Cayman) Inc.’s market cap is $442.25B.
When is Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date?
Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date is Mar 23, 2027 which is in 196 days.
How were Wuxi Biologics (Cayman) Inc.’s earnings last quarter?
Wuxi Biologics (Cayman) Inc. released its earnings results on Aug 25, 2026. The company reported $1.461 earnings per share for the quarter, beating the consensus estimate of $1.133 by $0.327.
Is Wuxi Biologics (Cayman) Inc. overvalued?
According to Wall Street analysts Wuxi Biologics (Cayman) Inc.’s price is currently Undervalued.
Does Wuxi Biologics (Cayman) Inc. pay dividends?
Wuxi Biologics (Cayman) Inc. does not currently pay dividends.
What is Wuxi Biologics (Cayman) Inc.’s EPS estimate?
Wuxi Biologics (Cayman) Inc.’s EPS estimate is 1.82.
How many shares outstanding does Wuxi Biologics (Cayman) Inc. have?
Wuxi Biologics (Cayman) Inc. has 4,152,929,700 shares outstanding.
What happened to Wuxi Biologics (Cayman) Inc.’s price movement after its last earnings report?
Wuxi Biologics (Cayman) Inc. reported an EPS of $1.461 in its last earnings report, beating expectations of $1.133. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) Inc.?
Currently, no hedge funds are holding shares in MX:2269N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wuxi Biologics (Cayman) Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$124.56 (88.73% Upside)
$124.56 (88.73% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Wuxi Biologics (Cayman) Inc.
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
2269N Company Deck
2269N Earnings Call
Q2 2026
0:00 / 0:00
2269N Stock 12 Month Forecast
Average Price Target
$124.56
▲(88.73% Upside)